CANY
ITOS

Caxton Associates (New York)’s iTeos Therapeutics ITOS Stock Holding History

Caxton Associates (New York)’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-30,695
Closed -$418K – 572
2023
Q1 		$418K Buy
+30,695
New +$550K 0.06% 296

Other funds holding ITOS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Caxton Associates (New York)'s ITOS Position: Q2 2023 in Review

Caxton Associates (New York) sold out of iTeos Therapeutics (ITOS) in Q2 2023, closing a stake of 30,695 shares — an estimated $418K sold.

Caxton Associates (New York) first reported a position in ITOS in Q1 2023 and held it in 1 quarter. The position peaked at $418K in Q1 2023. 146 funds tracked by Wall St. Rank hold ITOS as of Q2 2023.

  • Caxton Associates (New York) reported no remaining iTeos Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Caxton Associates (New York) sold 30,695 iTeos Therapeutics shares in Q2 2023, an estimated $418K.
  • Caxton Associates (New York) first reported a position in iTeos Therapeutics in Q1 2023 and held it in 1 quarter.
  • Caxton Associates (New York)'s iTeos Therapeutics position peaked at $418K in Q1 2023.
  • 146 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q2 2023.

Based on Caxton Associates (New York)'s 13F filing for Q2 2023, filed 15 Aug 2023.